Hong Kong Baptist University, the Chinese University of Hong Kong and Shanghai Jiao Tong University jointly published a systematic review of sclerostin inhibitors drug discovery

Recently, Professor Zhang Ge’ team from the Law Institute of Translational Medicine of Bone and Joint Diseases of Hong Kong Baptist University, Professor Zhang Baoting’s team from the School of Chinese Medicine at the Chinese University of Hong Kong, and Professor Zhang Zhenlin’s team from the Osteoporosis Department of the Sixth People's Hospital of Shanghai Jiao Tong University all served as co-corresponding authors, and jointly published a systematic review titled "Drug discovery of sclerostin inhibitors" in the journal Acta Pharmaceutica Sinica B (IF=11.413). Dr. Yu Sifan (postdoctoral fellow) from the Institute of Precision Medicine and Innovative Drugs of Hong Kong Baptist University, Dr. Li Dijie (postdoctoral fellow) from the Law Institute of Translational Medicine of Bone and Joint Diseases at Hong Kong Baptist University, and Zhang Ning (doctoral candidate) from the School of Chinese Medicine at the Chinese University of Hong Kong were Co-first authors of this review.

Sclerostin is a protein secreted by osteocytes and there are three loop-like domains with the central regions of sclerostin (loop 1, loop 2 and loop 3) (Figure 1a). Sclerostin antagonizes the Wnt signaling pathway by interacting with low-density lipoprotein receptor-related protein 5/6, thereby inhibiting bone formation and promoting bone resorption.